|
Vol. 11.27 – 13 July, 2022
|
|
|
|
|
|
Investigators demonstrated that lower expression of MAN1A1 in glioma stem cells resulted in the formation of high-mannose type N-glycan on CD133. [Advanced Science]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Scientists reported that little characterized cysteine-rich protein 1 (CRIP1) was upregulated in hepatocellular carcinoma and associated with poor prognosis. [EMBO Journal]
|
|
|
|
|
Investigators found that PFK158 treatment and PFKFB3 knockdown enhanced the ABCG2-interacting drugs doxorubicin, etoposide, and 5-fluorouracil in reducing cell viability under conditions of enriched CSCs. [Oncogene]
|
|
|
|
|
Researchers built a 3D in vitro model system of bone marrow (BM) organoids that recapitulated several structural and cellular components of native BM.
[APL Bioengineering]
|
|
|
|
|
To determine the regulatory action of NOTCH1-cMYC signaling in CSC maintenance, scientists evaluated the effect of a selective NOTCH1 inhibitor, crenigacestat, on CSC capacities in anaplastic thyroid cancer.
[Thyroid]
|
|
|
|
|
The authors investigated the photothermal effect of gold nanorods on human neuroblastoma CD133+ CSCs via autophagic cell death.
[Scientific Reports]
|
|
|
|
|
Scientists prospectively collected circulating tumor cell data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in their QUINTETT esophageal cancer randomized trial.
[BMC Cancer]
|
|
|
|
|
The authors analyzed 29 stem cell collections of 19 adult patients at a median age of 27 years mobilized after vincristine, ifosfamide, doxorubicine, and etoposide, dactinomycin, and ifosfamide chemotherapy.
[Transfusion]
|
|
|
|
|
Scientists explored whether casticin suppressed stemness in cancer stem-like cells obtained from human cervical cancer and the underlying mechanism. [Chinese Journal of Integrative Medicine]
|
|
|
|
|
|
The selective persistence of rare leukemic stem cells following therapy-induced remission implies unique resistance mechanisms of leukemic stem cells towards conventional therapeutic strategies and that leukemic stem cells represent the cellular origin of relapse. [Journal of Internal Medicine]
|
|
|
|
|
|
The Medical Research Council, Cancer Research UK, and Wellcome have announced £1 billion of funding for the Francis Crick Institute helping secure the future of the UK as a scientific powerhouse. [The Francis Crick Institute]
|
|
|
|
|
|
September 12 – 14, 2022 Liverpool, England, United Kingdom
|
|
|
|
|
|
|
The Chinese University of Hong Kong – Hong Kong, China
|
|
|
|
|
Albert Einstein College of Medicine – Bronx, New York, United States
|
|
|
|
|
Université catholique de Louvain – Brussels, Belgium
|
|
|
|
|
Fred Hutchinson Cancer Research Center – Seattle, Washington, United States
|
|
|
|
|
Boehringer Ingelheim – Vienna, Austria
|
|
|
|
|